DeepMed Research

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

Phase 2

Completed

Conditions: Overweight
Obesity

Interventions: Drug: pramlintide acetate 360 mcg
Drug: metreleptin
Drug: placebo-metreleptin 1 mL
Drug: placebo-pramlintide 600 uL
Drug: Pramlintide acetate 180 mcg

First Posted Date: 2006-10-26

Last Posted Date: 2015-04-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 177

Registration Number: NCT00392925

Locations: 🇺🇸
Research Site, Olympia, Washington, United States

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Phase 4

Completed

Conditions: Heart Failure
Ventricular Dysfunction, Left

Interventions: Drug: Captopril
Drug: Enalapril
Drug: Lisinopril
Drug: Ramipril
Drug: Trandolapril
Drug: Bisoprolol
Drug: Carvedilol
Drug: Metoprolol succinate
Drug: Candesartan
Drug: Valsartan
Drug: Eplerenone
Drug: Spironolactone
Drug: Diuretics
Drug: HF treatment according to Swedish guidelines
Procedure: Blood samples
Procedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)

First Posted Date: 2006-10-25

Last Posted Date: 2012-06-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 252

Registration Number: NCT00391846

Locations: 🇸🇪
Research Site, Vaxjo, Sweden

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

Phase 3

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Clopidogrel
Drug: Ticagrelor

First Posted Date: 2006-10-25

Last Posted Date: 2012-03-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 18624

Registration Number: NCT00391872

Locations: 🇬🇧
Research Site, Swansea, United Kingdom

Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response

Phase 4

Completed

Conditions: Gastroesophageal Reflux

First Posted Date: 2006-10-25

Last Posted Date: 2008-01-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 2000

Registration Number: NCT00392002

Locations: 🇨🇦
Research Site, Toronto, Ontario, Canada

Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: Ciclesonide

First Posted Date: 2006-10-25

Last Posted Date: 2017-02-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 528

Registration Number: NCT00392288

Locations: 🇲🇽
Sanofi-Aventis, Mexico, Mexico
🇵🇱
sanofi-aventis Poland, Warszawa, Poland
🇭🇺
Sanofi-Aventis Hungaria, Budapest, Hungary

and more 3 locations

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder

Phase 3

Completed

Conditions: Anxiety Disorders

Interventions: Drug: Quetiapine XR
Drug: Placebo

First Posted Date: 2006-10-18

Last Posted Date: 2012-04-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 450

Registration Number: NCT00389064

Locations: 🇺🇦
Research Site, Vinnitsa, Ukraine

Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2006-10-18

Last Posted Date: 2009-05-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 75

Registration Number: NCT00389389

Locations: 🇺🇸
Research Site, Houston, Texas, United States

Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

First Posted Date: 2006-10-17

Last Posted Date: 2010-04-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 338

Registration Number: NCT00388973

Locations: 🇺🇦
Research Site, Vinnitsa, Ukraine

Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults

Phase 3

Terminated

Conditions: Asthma, Bronchial

First Posted Date: 2006-10-09

Last Posted Date: 2010-12-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 654

Registration Number: NCT00385593

Locations: 🇪🇸
Research Site, Zaragoza, Spain

A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)

Phase 3

Completed

Conditions: Rhinitis, Allergic, Seasonal
Hay Fever

First Posted Date: 2006-10-06

Last Posted Date: 2016-11-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 500

Registration Number: NCT00384475

Locations: 🇨🇦
Altana Pharma/Nycomed, Ontario, Mississauga, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy